P/E ratio for Aerie Pharmaceuticals (AERI)
P/E ratio as of May 2024 (TTM): -20.3
According to Aerie Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -20.3333. At the end of 2021 the company had a P/E ratio of -4.31.
P/E ratio history for Aerie Pharmaceuticals from 2013 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | -4.31 | |
| 2019 | -5.49 | -15.55% |
| 2018 | -6.50 | -55.69% |
| 2017 | -14.7 | 31.87% |
| 2016 | -11.1 | 31.67% |
| 2015 | -8.45 | -42.07% |
| 2014 | -14.6 | 43.52% |
| 2013 | -10.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Merck MRK | 70.4 | -446.27% | 🇺🇸 USA |
 Lexicon Pharmaceuticals
LXRX | -2.50 | -87.70% | 🇺🇸 USA |
 Insmed INSM | -4.87 | -76.05% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.